Nippon Shinyaku gains Japanese rights to Labopharm's once-daily tramadol
This article was originally published in Scrip
The mid-sized Japanese company Nippon Shinyaku has acquired exclusive development and commercial rights in its home market to Labopharm's once-daily oral formulation of the analgesic tramadol.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.